Catecholamine-Secreting Tumors in Pediatric Patients With Cyanotic Congenital Heart Disease.
Swashti AgarwalIshita JindalAndrea BalazsDavid PaulPublished in: Journal of the Endocrine Society (2019)
Catecholamine-secreting tumors are rare among the pediatric population but are increasingly being reported in children with sustained hypoxia secondary to cyanotic congenital heart disease (CCHD). With this review, we report the clinical characteristics of these tumors in children with CCHD. The articles included in the present review were identified using PubMed through February 2019. A manual search of the references retrieved from relevant articles was also performed. Pheochromocytomas and paragangliomas (PPGL) in children are commonly associated with high-risk germline or somatic mutations. There is evidently a higher risk of tumorigenesis in children with CCHD as compared with the general pediatric population, even in the absence of susceptible gene mutations. This is due to molecular mechanisms involving the aberrant activation of hypoxia-response elements, likely secondary to sustained hypoxemia, resulting in tumorigenesis. Due to overlapping symptoms with CCHD, the diagnosis of PPGL may be delayed or missed in these patients. We studied all previously reported PPGL cases in children with CCHD and reviewed phenotypic and biochemical features to assess for contributing factors in tumorigenesis. Larger studies are needed to help determine other potential predisposing factors and to establish screening guidelines in this high-risk population. A delay in diagnosis of the PPGL tumors can lead to exacerbation of cardiac failure, and therefore early diagnosis and intervention may provide better outcomes in these patients, necessitating the need for regular surveillance. We recommend routine biochemical screening in patients with sustained hypoxia secondary to CCHD.
Keyphrases
- congenital heart disease
- young adults
- end stage renal disease
- ejection fraction
- newly diagnosed
- prognostic factors
- randomized controlled trial
- endothelial cells
- chronic obstructive pulmonary disease
- heart failure
- gene expression
- risk assessment
- type diabetes
- clinical practice
- intensive care unit
- adipose tissue
- patient reported outcomes
- copy number
- human health